{
    "name": "fluticasone topical",
    "comment": "Rx",
    "other_names": [
        "Cutivate"
    ],
    "classes": [
        "Corticosteroids",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/cutivate-fluticasone-topical-343524",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; observational studies suggest an increased risk of low birth weight infants with use of greater than 300 grams of potent or very potent topical corticosteroids during pregnancy; advise pregnant women that therapy may increase risk of having a low birth weight infant and to use drug on smallest area of skin and for shortest duration possible"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, subcutaneous administration to pregnant mice, rats, and rabbits during organogenesis caused malformations characteristic of corticosteroids in each species; available data do not allow calculation of relevant comparisons between systemic exposure of fluticasone propionate observed in animal studies to systemic exposure that would be expected in humans after topical use"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk, its effects on breastfed infant, or on milk production; not known whether topical administration could result in sufficient systemic absorption to produce detectable quantities in human milk",
            "Developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for drug and any potential adverse effects on breastfed child from therapy or from underlying maternal condition",
            "To minimize potential exposure to breastfed infant via breast milk, use on smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women not to apply drug directly to nipple and areola prior to breastfeeding to avoid direct infant exposure"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Underlying infection",
                "Skin atrophy",
                "Perioral dermatitis",
                "Rosacea",
                "Ophthalmic use"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Safety/efficacy in peds use longer than 4 wk not established",
                "Ointment not indicated for atopic dermatitis",
                "Use med to very high potency for <2 wk to reduce local and systemic side effects",
                "Use low potency for chronic therapy",
                "Reversible HPA axis suppression and resulting clinical glucocorticoid insufficiency can occur during or after withdrawal of treatment; risk factors include use over large surface area, prolonged use, use under occlusion, altered skin barrier, liver failure, and young age; children may exhibit greater susceptibility to corticosteroid-induced HPA axis suppression and Cushing's syndrome due to larger skin surface area to body weight ratio; modify use if HPA axis suppression is suspected;",
                "Avoid medium to very high potency on face, folds, groin because can increase steroid absorption",
                "Use lower potency for children (ie, increase BSA/kg, therefore increase systemic absorption)",
                "Contains imidurea as excipient which releases formaldehyde as a breakdown product; may cause allergic sensitization or irritation upon contact",
                "May cause irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, hypertrichosis, and miliaria; especially with high-potency or occlusive dressings"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Pruritus",
            "percent": "2.9"
        },
        {
            "name": "Dryness",
            "percent": "1.2"
        },
        {
            "name": "Skin irritation",
            "percent": "3"
        },
        {
            "name": "Eczema",
            "percent": "1"
        },
        {
            "name": "Telangiectasia",
            "percent": "2-5"
        },
        {
            "name": "Numbness of fingers",
            "percent": "1"
        },
        {
            "name": "Burning",
            "percent": "2"
        },
        {
            "name": "Folliculitis",
            "percent": null
        },
        {
            "name": "Acneiform lesions",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Hypertrichosis",
            "percent": null
        },
        {
            "name": "Lightheadedness",
            "percent": null
        },
        {
            "name": "Viral",
            "percent": null
        },
        {
            "name": "Warts",
            "percent": null
        },
        {
            "name": "Impetigo",
            "percent": null
        },
        {
            "name": "Skin infection",
            "percent": null
        },
        {
            "name": "Striae",
            "percent": null
        },
        {
            "name": "Pigmentation changes",
            "percent": null
        },
        {
            "name": "HPA suppression",
            "percent": null
        },
        {
            "name": "with higher potency used",
            "percent": null
        },
        {
            "name": "wk",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Cushing syndrome",
            "percent": null
        },
        {
            "name": "Sepsis",
            "percent": null
        },
        {
            "name": "Hemorrhage reported",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        }
    ]
}